SLC5A2 and endothelial dysfunction: SGLT2 inhibitorsEmpagliflozin: Empagliflozin is a novel SGLT2 inhibitor, the underlying mechanisms of which include ameliorating hyperglycemia, preventing the development of endothelial dysfunction, reducing oxidative stress, and improving metabolic profiles.596 Empagliflozin can prevent the loss of skin intraepidermal nerve fibers and mesangial matrix expansion597 and a potential therapeutic effect on DPN.